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Hirohisa Nakamae,1 Katharine A. Kirby,1 Brenda M. Sandmaier,1,2 Lalita Norasetthada,1
David G. Maloney,1,2 Michael B. Maris,3 Chris Davis,1 Lawrence Corey,1,2
Rainer Storb,1,2 Michael Boeckh1,2Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell
chimerism for up to half a year with prolonged presence of host T cell immunity. In this study, we examined
whether this translates into differences in the risks and/or severity of cytomegalovirus (CMV) infection and
disease.We analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489myeloablative
hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive recipients, no difference in the
overall hazards of CMV infection at any level (adjusted hazard ratio [adj. HR] 0.9, 95% confidence interval
[95% CI]: 0.7-1.0, P 5 .14) was noted; however, NM-HCTwas associated with a lower risk of high-grade
CMV infection (adj. HR 0.7, 95% CI: 0.5-0.9, P 5 .02). CMV disease rates were similar between the groups
during the first 100 days after HCT, but NM-HCTrecipients had an increased risk of late CMV disease (adj.
HR 2.0, 95% CI 1.2-3.4). The increased risk of late CMV disease after NM-HCTwas pronounced during the
earlier years of the study period, but not detectable in more recent years. Contrary to earlier reports, sur-
vival following CMV disease was not reduced after NM-HCTwhen compared to M-HCT recipients. These
results suggest that residual host cells after NM-HCT reduce progression to higher CMV viral load in
NM-HCT recipients; however, this effect does not appear to protect against serious complications of
CMV. Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in
M-HCT recipients.
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CMV diseasesINTRODUCTION
NonmyeloablativeHCT(NM-HCT) is nowwidely
used in patients with hematologic and nonhematologic
malignancies who are ineligible for myeloablative
HCT (M-HCT) because of advanced age or comorbid-
ities [1-3]. NM-HCT includes reduced or minimally
intensive conditioning therapy before transplantation,1Fred Hutchinson Cancer Research Center, Seattle,
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6/j.bbmt.2009.02.009combined with more intensive immunosuppression af-
ter transplantation. The nonmyeloablative regimen
used in Seattle consists of low-dose total body irradia-
tion (TBI) 2 Gy with or without fludarabine (Flu) fol-
lowed by cyclosporine (CsA) or tacrolimus and
mycophenolate mofetil (MMF) as postgrafting immu-
nosuppression [3-9]. This regimen causes minimal tox-
icity, and results in initial establishment of mixed host/
donor T cell chimerism for up to approximately 6
months. Thus, risk or severity of viral infections, such
as cytomegalovirus (CMV) infection, may be reduced.
We initially reported that the time of CMV disease
onset was delayed after HLA matched-related
NM-HCT, supporting the hypothesis that extended
presence of host memory immune responses after
NM-HCTmight play a role in protection against early
CMV infection [10-12]. We also reported that the risk
of CMV disease was similar after NM-HCT from
HLA matched-unrelated and -related donors [13].
Our study also suggested that CMV disease might be
associated with a lower mortality in NM-HCT
Biol Blood Marrow Transplant 15:694-703, 2009 695CMV after nonmyeloablative conditioningrecipients [10]. These studies were done early after the
technique was introduced, which limited the power of
statistical analyses because of small sample sizes.
This report examines the incidence, risk, and out-
come of CMV infection in a large cohort of recipients
undergoing NM-HCT and compared the outcomes
with those of contemporaneous M-HCT recipients.PATIENTS AND METHODS
This retrospective analysis was approved by the
institutional review board of the Fred Hutchinson
Cancer Research Center (FHCRC; Seattle, WA).
Informed consent was provided according to the
Declaration of Helsinki.
Patients
We compared outcomes in 537 consecutive
patients who received NM-HCT between December
1997 and December 2005, at the FHCRC and 2489
patients who received M-HCT between January
1995 and December 2005, at the FHCRC (Table 1).
Recipient and donor age, proportions of a prior
transplant history, peripheral stem cell source, CMV
high-risk patients, and MMF use as a postgrafting
immune suppressant were significantly higher in
NM-HCT compared to M-HCT. NM-HCT became
more common in the later years, and no T cell-deple-
tion regimen was used in NM-HCT.
The CMV risk was stratified into 3 groups: low
(recipient negative and donor negative); intermediate (re-
cipient negative and donor positive); and high (recipient
positive and either donor negative or positive) based on
recipient and donor CMV serostatus before HCT.
Preparative Conditioning Regimens
and Sources for HCT
Three hundred forty-eight (64.8%) NM-HCT
recipients received fludarabine (Flu; 30 mg/m2/day
for 3 consecutive days) and low-dose TBI (2 Gy, day
0), whereas 90 patients (16.8%) received low-dose
TBI (2Gy, day 0) alone. Patients in theM-HCTgroup
received different types of conditioning. The most
common regimens consisted of cyclophosphamide
(Cy; 60 mg/kg/day for 2 consecutive days) followed
by TBI (12-13.2 Gy) or busulfan (Bu; 4 mg/kg/day
for 4 consecutive days) followed by Cy (60 mg/kg/
day for 2 consecutive days) in 805 (32.3%) and 779
(31.3%) patients, respectively (data not shown). The
distribution of stem cell sources used in NM-HCT
and M-HCT is shown in Table 1.
Prophylaxis and Diagnosis of Graft-versus-Host
Disease (GVHD)
GVHD prophylaxis regimens are shown in Table
1. NM-HCT patients most commonly received CsAand MMF orally as immune suppressants post
HCT. MMF was administered 15 mg/kg orally twice
a day from day 0 to day 27 and discontinued for the
HLA matched-related NM-HCTs and MMF 15
mg/kg orally 2 or 3 times a day from day 0 to day
40, with a taper to day 96 for the unrelated NM-
HCTs. For the single HLA-antigen and combined
HLA-antigen and allele mismatched NM-HCTs, 15
mg/kg MMF was given 3 times a day and was tapered
at day 100 over 2 months [5-9].
M-HCT patients most commonly received the
combination of CsA and MTX. CsA was given at
a dose of 1.5 mg/kg intravenously (i.v.) twice a day or
6.25 mg/kg orally twice a day. MTX was administered
i.v. at a dose of 15 mg/m2 on day 1, and 10 mg/m2 on
day 3, 6, and 11. Diagnoses of acute or chronic GVHD
(aGVHD, cGHVD) were performed according to es-
tablished criteria [14,15].Infection Surveillance and Preemptive Therapy
against CMV
CMV surveillance including polymerase chain
reaction (PCR), pp65 antigenemia (AG), and blood
culture was performed on a weekly basis until day
100. After day 100, surveillance and preemptive ther-
apy were recommended for CMV intermediate and
high-risk patients on a weekly or biweekly basis.
Patients were monitored for the development of
CMV infection and diseases until day 365. CMV
pp65 AG was quantified as the average number of pos-
itive cells per 200,000 peripheral blood leukocytes and
quantitative detection of CMV DNA in plasma by
PCR was performed as described [16].
Ganciclovir (GCV) treatment was started when
CMV AG/PCR became positive during the first
100 days after HCT. All patients with CMV AG at any
level received GCV (5 mg/kg i.v. twice daily) for 7 to
14 days as induction therapy, followed by maintenance
therapy with a half dose of GCV (5 mg/kg i.v. daily) or
valganciclovir 900 mg once a day orally until negative
surveillance testing was detected or day 100. After day
100, preemptive therapy consisting of i.v. GCV or val-
ganciclovir induction, followed bymaintenance therapy,
was recommended when CMV AG became positive or
whenPCRwas.1000 copies/mL.GCVwas substituted
with foscarnet in patients with neutropenia.
Between January 1995 and November 1998,
no patients received acyclovir for varicella zoster
virus (VZV) prevention; but herpes simplex virus
(HSV)-positive recipients were given acyclovir,
250 mg/m2 twice daily from day27 until engraftment
and resolution of mucositis. From November 1998
until May 2002, VZV seropositive HCT recipients re-
ceived prophylaxis against VZV (acyclovir 250 mg/m2
i.v., followed by 800 mg orally or valacyclovir 500 mg
orally; all drugs given twice per day for 1 year after
Table 1. Characteristics of the Study Cohort
M-HCT (n 5 2489) NM-HCT (n 5 537)
Variable Number (%) Number (%) P-Value
Median (range) age, years
Patient 39.8 (0.5-67.0) 54.2 (0.5-74.5) <.0001
Donor 38.2 (0.7-81.7) 42.5 (1.3-83.3) <.0001
Sex
Male 1422 (57.1) 334 (62.2)
Female 1067 (42.9) 203 (38.6) .03
Donor sex
Male 1399 (56.2) 284 (52.9)
Female 1087 (43.7) 253 (47.1) .26
Recipient race
Caucasian 2015 (81.0) 470 (87.5)
Other/unknown 474 (19.0) 67 (12.5) <.001
Donor race
Caucasian 1457 (58.5) 269 (50.1)
Other/unknown 1032 (41.5) 268 (49.9) <.001
Year of transplantation
1995-1997 834 (33.5) 1 (0.2)
1998-2000 716 (28.8) 116 (21.6)
2001-2003 578 (23.2) 225 (41.9)
2004-2005 361 (14.5) 195 (36.3) <.0001
Prior transplant (auto and/or allo)
Yes 74 (3.0) 202 (37.6)
No 2415 (97.0) 335 (62.4) <.0001
Source of stem cell
BM 1431 (57.5) 49 (9.1)
PBSC 1015 (40.8) 487 (90.7)
Cord 43 (1.7) 1 (0.2) <.0001
HLA matching
Matched related 1017 (42.0) 221 (44.0)
Mismatched related/unrelated 1404 (56.4) 281 (52.3) .28
CMV seropositive
Yes 1260 (50.6) 311 (57.9)
No 1228 (49.3) 225 (41.9) <.01
Donor CMV seropositive
Yes 984 (39.5) 230 (42.8)
No 1503 (60.4) 307 (57.2) .30
CMV risk
Low 894 (35.9) 152 (28.3)
Intermediate 334 (13.4) 73 (13.6)
High 1260 (50.6) 311 (57.9) <.01
Disease diagnosis
AA 67 (2.7) 2 (0.4)
ALL 346 (13.9) 21 (3.9)
AML 702 (28.2) 143 (26.6)
CLL 18 (0.7) 40 (7.5)
CML 669 (26.9) 18 (3.4)
HL 14 (0.6) 46 (8.6)
MDS 465 (18.7) 41 (7.6)
MM 38 (1.5) 83 (15.5)
NHL 106 (4.3) 98 (18.3)
Congenital disorders 19 (0.8) 16 (3.0)
Other 44 (1.8) 29 (5.4) <.0001
T cell depletion regimen
Yes 270 (10.9) 0 (0.0)
No 2219 (89.2) 537 (100.0) <.0001
Acute GVHD prophylaxis
Calcineurin inhibitor only 27 (1.1) 17 (3.2)
Calcineurin inhibitor +MMF 66 (2.7) 495 (92.2)
Calcineurin inhibitor +MTX 2294 (92.2) 5 (0.9)
Other 101 (4.1) 20 (3.7) <.0001
AA indicates aplastic anemia; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic
myelogenous leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CMV, cyto-
megalovirus; BM, bone marrow; PBSC, peripheral blood stem cell; acute GVHD, acute graft-versus-host disease; MMF, mycophenolate mofetil; MTX,
methotrexate.
T cell depletion regimens are those containing antithymocyte globulin or anti-CD3 antibody, BC3.
P-values from chi-square test, Fisher’s exact test, or Wilcoxon rank-sum test as appropriate.
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Table 2. The Incidences of CMV Infection and Disease
Endpoints
Incidence
in M-HCT
Incidence
in NM-HCT P-Value
CMV infection by day 100
Low risk 0.03 0.02 .64
Intermediate risk 0.15 0.21 .27
High risk 0.66 0.62 .08
High-grade CMV infection
by day 100
Low risk 0.01 0.00 .33
Intermediate risk 0.05 0.09 .20
High risk 0.25 0.14 <.0001
CMV disease by day 100
Low risk 0.01 0.01 .52
Intermediate risk 0.01 0.02 .68
High risk 0.10 0.07 .11
CMV disease by 1 year
Low risk 0.01 0.01 .96
Intermediate risk 0.03 0.03 .95
High risk 0.15 0.15 .50
Late CMV disease
Low risk 0.01 0.00 .35
Intermediate risk 0.02 0.04 .68
High risk 0.09 0.11 .52
CMV indicates cytomegalovirus; M-HCT, myeloablative hematopoietic
cell transplantation; NM-HCT, nonmyeloablative hematopoietic cell
transplantation.
Biol Blood Marrow Transplant 15:694-703, 2009 697CMV after nonmyeloablative conditioningtransplantation (valacyclovir was preferred for patients
who received .0.5 mg/kg per day of steroids). HCT
patients undergoing transplantation after May 2002
received the same regimen until 1 year after
transplantation. In patients who were still receiving
inmmunosuppression at 1 year, acyclovir/valacyclovir
prophylaxis was continued until 6 months after
discontinuation of all immunosuppression [17].
Definitions of CMV Infection and Disease
CMV AG was diagnosed by blood pp65 antigen
testing, CMV viremia by positive blood culture or
shell vial centrifugation culture [10], and detection of
CMV DNA by PCR [16]. CMV disease was defined
by established criteria [18].
Study Endpoints
In the present study, we evaluated the following 6
endpoints: (1) CMV infection (any CMV AG/DNA
detection) by day 100; (2) high-grade CMV infection
(CMV AG .10/200,000 peripheral blood leukocytes
orPCR.1000copies/mLbyday100; (3)CMVviremia
(culture) by day 100; (4) CMV disease by day 100 and
1 year; (5) late CMV disease, which occurred after
day 100 after HCT; (6) survival after CMV disease.
Statistical Analysis
Characteristics of NM-HCT and M-HCT pa-
tients were summarized using frequency counts and
percentages for categoric variables and medians and
ranges for continuous variables.
The cumulative incidences of CMV infection,
CMV high-grade infection, CMV disease, and late
CMV disease were compared between NM-HCT
and M-HCT groups, with subsequent transplantation
or death considered competing risks. Cumulative inci-
dence curves for these endpoints also were stratified by
CMV risk groups defined by donor and recipient sero-
positivity and by transplant year groupings between
1995 and 2005. The probability of survival was esti-
mated by the Kaplan-Meier method. Hazards were
compared using the log-rank test. The median times
to onset of CMV disease were compared by the Wil-
coxon rank sum test.
Univariate andmultivariate Cox regressionmodels
were used to estimate hazard ratios and 95% confi-
dence intervals (95% CI). Cox regression analyses for
CMV infection, high-grade CMV infection, CMV
viremia, and CMV disease were performed in the
CMV high-risk group. CMV viremia was analyzed in
just a slightly smaller subset because CMV viremia
was tested only through 12/2003. Covariates included
recipient/donor age and sex, recipient/donor race,
donor CMV serostatus, sex mismatch, HLA disparity,
donor relationship, intensity of conditioning, stem cell
source, HSV type I, II serostatus, T cell-depleted con-ditioning, transplantation year, disease risk, GVHD
prophylaxis, aGVHD, and cGVHD. Additionally,
CMV risk group and maximum values of CMV AG
and PCR testing were evaluated as risk factors for
CMV disease.
aGVHD and cGVHD, CMV AG, and PCR test-
ing were analyzed as time-dependent variables. Vari-
ables less than P 5 .05 in the univariate models were
candidates for the multivariate models. Nonmyeloa-
blative versus myeloablative conditioning was forced
into multivariate models of all endpoints.RESULTS
CMV Infection and Viremia
Low- and intermediate-risk group (D2/R2,
D1/R2)
The cumulative incidences of CMV infection by
day 100 were similar between NM-HCT and M-
HCT in CMV low- and intermediate-risk groups.
High-grade CMV infection was very rare, particularly
in CMV low-risk groups and was not noted in any low-
risk NM-HCT patient (Table 2).
High-risk group (D2/R1, D1/R1)
In CMV high-risk group (n 5 1571), there were
trends toward lower CMV infection and high-grade
CMV infection rates in NM-HCT (Table 2 and
Figure 1). When high viral load was analyzed,
stratified by HLA-matched related versus unrelated/
HLA-mismatched related donor status in the CMV
high-risk group, the lower incidence of high-grade
Figure 1. Cumulative incidences of any and high-grade CMV infections in CMV high-risk patients. The probabilities of (a) any CMV infection and (b)
high-grade CMV infection (CMV AG .10 cells/200,000 PBL or CMV DNA .1000 copies/mL of plasma) in CMV high-risk patients are displayed. The
dashed line indicates nonmyeloablative hematopoietic cell transplantion (NM-HCT) and the solid line indicates myeloablative hematopoietic cell trans-
plantion (M-HCT). P-values were calculated by the log-rank test.
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HLA-matched related and unrelated/HLA-mismatched
related settings (Figure 2). Unrelated and HLA-
mismatcheddonor statuswas associatedwith a somewhat
higher cumulative incidence of high-grade CMV infec-
tion at day 100 than HLA-matched related donor status
(Figure 2). This effect was seen in both M-HCT and
NM-HCT recipients. In the CMV high-risk group,
other factors associated with increased risks of any
CMV infection were recipient age and aGVHD (III or
IV). Other factors associated with an increased risk of
high-grade CMV infection were recipient race (other
than Caucasian) and aGVHD (Table 3).
Among seropositive patients transplanted between
1995 and 2003 (n 5 1263), the incidence of CMV
viremia (culture proven) by day 100 was significantly
lower in NM-HCT compared with M-HCT (10%
versus 19%, P\ .001). However, in the multivariate
model, the significance was not sustained. Other risk
factors for CMV viremia were recipient race (other
than Caucasian) (adj. hazard ratio [HR] 1.9, 95% CI:
1.2-3.0, P\ .01) and aGVHD II to IV (adj. HR 3.4,Figure 2. Cumulative incidences of CMV high-grade infection in CMV hi
mismatched donor. (A) myeloablative HLA-matched related donor, (B) myeloa
HLA-matched related donor, (D) nonmyeloablative unrelated/HLA-mismatche95% CI: 2.2-5.2, P\ .0001). CMV viremia was less
common in the later years of the study period (2001-
2003) compared to 1995-1997 (adj. HR 0.4, 95% CI:
0.6-0.6, P\ .0001) (data not shown).Time to CMV Negativity after Start
of Preemptive Therapy
As a surrogate marker for duration of anti-CMV
treatment, we compared the duration from first posi-
tive to the first negative AG/PCR result between
NM-HCT and M-HCT and found no difference in
all patients (median [range]:7 [0-13] versus 7 [0-50]
days, respectively, P 5 .98) or in patients at high risk
for CMV (seropositive recipients) (median [range]:7
[0-13] versus 7 [0-50] days, respectively, P 5 .97).CMV Disease and Survival after CMV Disease
Low-and intermediate-riskgroup(D2/R2,D1/R2)
Among CMV low- and intermediate-risk groups,
there was no significant statistical difference in thegh-risk patients stratified by matched-related versus unrelated/HLA-
blative unrelated/HLA-mismatched related donor, (C) nonmyeloablative
d related donor.
Table 3. Univariate and Multivarite Analyses of Risk Factors for CMV Infection in CMV High-Risk Group
CMV Infection*
CMV High-Grade
Infection*
Factors Univariate HR (95%CI) P adj. HR (95%CI) P Univariate HR (95%CI) P adj. HR (95%CI) P
NM-HCT 0.9 (0.7-1.0) .08 0.9 (0.7-1.0) .14 0.5 (0.4-0.7) <.0001 0.7 (0.5-0.9) .02
Recipient age $ 41 years 1.3 (1.1-1.4) <.001 1.5 (1.3-1.7) <.0001 0.9 (0.8-1.1) .46 — —
Recipient race
(other than Caucasian)
1.2 (1.0-1.4) .01 1.1 (0.9-1.4) .23 1.2 (1.0-1.6) .08 1.4 (1.1-1.9) <.01
Donor CMV positive 1.0 (0.9-1.1) .56 — — 0.7 (0.6-0.9) .002 0.7 (0.6-0.9) <.01
Related donor 0.8 (0.7-0.9) <.0001 0.9 (0.7-1.2) .46 0.7 (0.5-0.8) .0001 0.6 (0.4-1.0) .04
HSV1 positive (recipient) 0.7 (0.5-0.8) <.001 0.6 (0.5-0.8) <.001 1.0 (0.7-1.6) .92 — —
Acute GVHD (III or IV) 1.5 (1.3-1.8) <.0001 1.4 (1.2-1.6) <.0001 2.2 (1.8-2.8) <.0001 1.8 (1.4-2.3) <.0001
Year of transplant
1995-1997 1.0 1.0 1.0 1.0
1998-2000 0.8 (0.7-1.0) .01 0.8 (0.7-1.0) .01 0.7 (0.5-0.9) .006 0.7 (0.5-0.9) <.01
2001-2003 0.8 (0.7-1.0) .02 0.9 (0.7-1.1) .20 0.5 (0.4-0.7) <.0001 0.6 (0.4-0.8) <.001
2004-2005 0.8 (0.7-1.0) .04 0.8 (0.6-1.0) .05 0.4 (0.3-0.5) <.0001 0.4 (0.3-0.6) <.0001
adj. HR indicates adjusted hazard ratio; CI, confidence interval; NM-HCT, nonmyeloablative hematopoietic cell transplantation; CMV, cytomegalovirus;
HSV1, herpes simplex virus type 1; GVHD, graft-versus-host disease.
The factors that were statistically significant in either multivariate model of CMV infection or high-grade CMV infection, and NM-HCTare displayed.
*Total sample size of CMV high-risk patients is 1,571.
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NM-HCT and M-HCT (Table 2).
High-risk (D2/R1, D1/R1)
In the CMV high-risk group, the cumulative
incidence of CMV disease by day 100 (but not by
1 year) tended to be less frequent in NM-HCT
compared withM-HCT (Tables 2 and 4). A significant
decline of CMV disease incidence was noted after
2001 compared to 1995-2000 (Figure 3a and b). TheTable 4. Univariate and Multivariate Analyses of Risk Factors for C
CMV Disease*
Factors Univariate HR (95%CI) P adj. HR
NM-HCT 0.9 (0.7-1.3) .74 1.3 (
Donor sex (female) 1.3 (1.0-1.6) .08 1.4 (
Unrelated/HLA-mismatched 1.4 (1.1-1.8) <.01 1.2 (
HSV1 positive 2.0 (1.0-3.9) .04 2.3 (
Acute GVHD (III or IV) 2.7 (2.1-3.6) <.0001 2.1 (
Chronic GVHD 2.6 (1.8-3.8) <.0001 2.1 (
Acute (III or IV) or Chronic GVHD — —
Year of transplant
1995-1997 1.0 1.0
1998-2000 1.2 (0.9-1.7) .24 1.3 (
2001-2003 0.7 (0.5-0.9) .02 0.8 (
2004-2005 0.6 (0.4-0.9) .02 0.8 (
Max. CMV AG
0 1.0 1.0
>0-2/200,000 1.7 (1.1-2.5) .01 1.7 (
>2-10/200,000 1.6 (1.0-2.6) .05 1.4 (
>10/200,000 4.7 (3.3-6.8) <.0001 3.7 (
Max. CMV PCR (copies/mL)
0 1.0 1.0
0-1000 2.3 (1.4-3.8) <.01 2.4 (
>1000 2.4 (1.2-4.6) .01 3.2 (
Max. CMV AG>10/PCR >1000 before
day 100 (copies/mL)
— —
adj. HR indicates adjusted hazard ratio; CI, confidence interval; NM-HCT, nonm
HSV1, herpes simplex virus type 1; GVHD, graft-versus-host disease; AG, ant
The factors that were statistically significant in either multivariate model of C
*The sample size of CMV high-risk patients at risk for CMV disease is 1,571; the
day 100 and were at risk for late CMV disease is 1,109.cumulative incidence for CMV disease in CMV
high-risk NM-and M-HCT patients from 1995 to
2000 were 27% versus 18% (P 5 .25) compared to
12% versus 11% (P 5 .94) between 2001 and 2005
(Figure 3a and b). A significant delay in the onset of
CMV disease was observed in NM-HCT in the
high-risk CMV group (median day of onset; 106.5
[6.0-1273.0] versus 69.5 days [6.0-1775.0] P 5 .02).
Among NM-HCT, the cumulative incidences of
CMV disease at 1 year between HLA-matched relatedMV Disease in CMV High-Risk Group
Late CMV Disease*
(95%CI) P Univariate HR (95%CI) P adj. HR (95%CI) P
0.9-1.9) .12 1.2 (0.7-1.8) .52 2.0 (1.2-3.4) .01
1.1-1.7) .02 1.2 (0.8-1.8) .31 — —
0.7-2.1) .44 2.5 (1.7-3.9) <.0001 2.1 (1.4-3.3) <.01
1.2-4.5) .01 2.6 (0.8-8.5) .12 — —
1.6-2.7) <.0001 — — — —
1.4-3.0) <.0001 — — — —
— — 6.0 (2.6-13.6) <.0001 4.1 (1.8-9.5) <.01
1.0 1.0
0.9-1.8) .14 0.7 (0.4-1.8) .14 0.7 (0.4-1.1) .12
0.5-1.4) .44 0.5 (0.3-0.8) <.01 0.4 (0.2-0.8) <.01
0.5-1.3) .31 0.6 (0.3-1.0) .05 0.5 (0.3-0.9) .03
— —
1.1-2.5) .01 — — — —
0.9-2.3) .16 — — — —
2.5-5.4) <.0001 — — — —
— —
1.4-4.1) <.01 — — — —
1.6-6.5) <.01 — — — —
— — 2.8 (1.9-4.1) <.0001 2.0 (1.4-3.0) <.01
yeloablative hematopoietic cell transplantation; CMV, cytomegalovirus;
igenemia; PCR, polymerase chain reaction.
MV disease or late CMV disease, and NM-HCTare displayed
sample size of CMV high-risk patients who survived CMV-disease-free to
Figure 3. Cumulative incidences of CMV disease in CMV high-risk patients and late CMV disease. The probabilities of (a) CMV disease from1995 to
2000, (b) CMV disease from 2001 to 2005 in CMV high-risk patients, (c) late CMV disease from1995 to 2000, and (d) late CMV disease from 2000 to 2005
are displayed. The probability curves for late CMV were generated from all CMV high-risk patients who survived beyond day 100 without underlying
disease relapse. The dashed line indicates nonmyeloablative hematopoietic cell transplantion (NM-HCT) and the solid line indicates myeloablative he-
matopoietic cell transplantion (M-HCT). P-values were calculated by the log-rank test.
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very similar (15% versus 14%, P5 .87).
Other risk factors associated with CMV disease in
multivariate analysis were donor female sex, aGVHD,
cGVHD, HSV type I seropositivity, and positivity of
CMV AG and/or PCR (Table 4).
The probability of survival in CMV high-risk pa-
tients who developed CMV disease (n 5 226) wasFigure 4. Survival after CMV disease in CMV high-risk patients. The probabil
disease. The dashed line indicates nonmyeloablative hematopoietic cell transpla
cell transplantion (M-HCT). P-values were calculated by the log-rank test.not significantly different between NM-HCT and
M-HCT recipients (P 5 .88) (Figure 4).
Late CMV Disease
Low-and intermediate-riskgroup(D2/R2,D1/R2)
No significant statistically differences in incidences
were observed between MN-HCT and M-HCT. Lateity of survival after CMV disease in 226 high-risk patients who had CMV
ntion (NM-HCT) and the solid line indicates myeloablative hematopoietic
Biol Blood Marrow Transplant 15:694-703, 2009 701CMV after nonmyeloablative conditioningCMV disease was not observed in any CMV low-risk
NM-HCT patient (Table 2).
High-risk group (D2/R1, D1/R1)
No statistically significant differences in late CMV
disease incidences were detected between MN-HCT
and M-HCT in CMV high-risk group (Table 2).
Among all the risk groups, NM-HCT was signifi-
cantly associated with late CMV disease after adjust-
ment for multiple covariates (adj. HR 2.0, P 5 .01)
(Table 4). However, this was mainly driven by a high
incidence of late CMV disease during the earlier years
of the study period (Figure 3c and d). Additional risk
factors for late CMV disease were: HLA-mismatch
or unrelated donor, aGVHD (III or IV) or cGVHD
before day 100, and maximum CMV AG .10/PCR
. 1000 copies/mL before day 100. Furthermore, late
CMV disease was less common in more recent years
(2001-2005) compared to 1995-1997 (Table 4).
Secondary Invasive Bacterial and Fungal
Infection after CMV Infection
We compared the incidences of secondary bacte-
rial infection before day 100 and fungal infections
before 1 year after HCT between NM-HCT and
M-HCT. There was no significant difference in risk
of probable and definite invasive fungal infection
between NM-HCT and M-HCT in all CMV risk
groups (P 5 .77), nor in high-CMV-risk group
(P 5 .83).
Secondary invasive bacterial infections were less
common in NM-HCT (23% versus 28%, chi-square
value P\ .0001). There was a significant difference
in hazard of bacterial infection between NM-HCT
and M-HCT adjusted for CMV risk group (HR 5
0.6, 95% CI 5 0.5-0.8, P\ .0001); when the analysis
was restricted to the CMV high-risk group (seroposi-
tive recipients), a similar effect was seen (HR 5 0.7,
95% CI 5 0.5-0.9, P\ .01).DISCUSSION
We comprehensively examined risks and outcomes
of CMV infection and disease in a large cohort of uni-
formly treated patients that provided the necessary
power to analyze CMV endpoints in NM-HCT recip-
ients. NM-HCT recipients had similar rates of CMV
infection and disease compared to M-HCT, although
a delayed timing of disease and lower maximum CMV
viral loads were noted. Contrary to an earlier small
study that showed a trend toward improved outcome
of CMV disease in NM-HCT [10], the present study
did not show evidence of such an effect.
In a previous study, we demonstrated that
NM-HCT showed trends toward lower incidence of
CMV infection pp65 antigenemia, CMV viremia,and CMV disease during the first 100 days after
HCT. However, we did not show statistically signifi-
cant differences in the incidence of these CMV events
between NM-HCT and M-HCT, possibly because of
the small sample size [10]. In the present study, we
were able to provide statistical evidence that the inci-
dence of high CMV viral load in NM-HCT is lower
compared with M-HCT. This effect was seen in
both HLA mismatched-related or unrelated and
HLA matched-related HCT recipients (Figure 2).
Similar to an earlier study, there was a trend toward
a more profound reduction of high CMV load in
HLA-matched-related NM-HCT recipients than in
HLA-mismatched related or unrelated NM-HCT
recipients, but even with this large sample size, this
did not reach statistical significance (Figure 2). We
speculate that the strong immunosuppressants and/
or the high incidence and severity of GVHD in
HLA-mismatched related or unrelated HCT might
somewhat diminish the protection from persisting
host T cell immunity in NM-HCT. We confirmed
that the onset of CMV disease was delayed, which
resulted in a trend toward less CMV disease before
day 100 in NM-HCT recipients (Table 2). Collec-
tively, these data suggest that the residual CMV
specific host memory cells had a limited or no effect
on reactivation of CMV, but contributed to preventing
progression to higher levels of viral load, at least early
after less intensive conditioning. This is consistent
with laboratory studies that showed a persistence
of host memory T cells in HLA-matched related
NM-HCTrecipients [11,12].However, after complete
donor chimerism has been achieved in NM-HCT
recipients, the benefits of protection against CMV
infection seem to disappear. Our previous studies of
CMV immunity showed that, after day 100, there was
no difference in CMV-specific T cell immunity
between NM-HCT and M-HCT recipients [11,12].
Somewhat surprisingly, more patients developed
late CMV disease following NM-HCT compared to
M-HCT. Further analysis suggested that the effect
was driven by the earlier years of the study period
[10] (Figure 3c). This was likely because of less
virologic surveillance for late CMV infection and less
use of late preemptive therapy, possibly because of
the perception that infectious complications were
less frequent and/or severe [10]. Additionally, the
prolonged MMF prophylaxis or treatment, particu-
larly in the unrelated NM-HCT, possibly contributed
to more frequent incidence of late CMV disease in
NM-HCT than in M-HCT. In more recent years,
there was no increased risk of late CMV disease in
NM-HCT recipients (Figure 3d). Also, the overall
incidence of late CMV disease declined in both NM
and M-HCT recipients, likely because of extended
monitoring of CMV by PCR and increased use of
preemptive anti-CMV treatment beyond day 100.
702 Biol Blood Marrow Transplant 15:694-703, 2009H. Nakamae et al.Risk factors for late CMV disease seen in this study
(Table 4) were consistent with earlier reports by our
group and others [19-21].
Although we were unable to separate the effect of
GVHD on the risk of CMV endpoints in our previous
studies [10,13], in the current study, both aGVHD and
cGVHD were statistically significant risk factors for
early and late CMV disease in the current study.
This was consistent with previous reports [20].
The strengths of this study were the large sample
size permitting multivariate modeling, well-defined
and homogenous transplant protocols, highly stan-
dardized supportive care, CMV surveillance, and
a comprehensive and standardized workup of bron-
choalveolar lavage (BAL) and biopsy specimens
(including autopsy specimens). Limitations were the
retrospective nature of the analysis and that comedica-
tions could only be analyzed by protocol (as supposed
to on a per-patient basis). Also, the data might not
extend to different reduced-intensity protocols.
Furthermore, in this study, the majority of the
NM-HCT patients received peripheral blood stem
cells (PBSCs) (Table 1). Although we could not
detect a significant effect of the stem cell on CMV
outcomes in the multivariate models, NM-HCT
and PBSC use are tightly linked so we cannot
conclusively rule out an interaction between the 2
modalities [22].
In conclusion, this large study provided robust
data on the risk of CMV infection and disease in
recipients of NM-HCT. The study confirmed and
added statistical strength to some of the earlier find-
ings, including the delayed onset of CMV disease and
a lower risk of progression to higher viral loads dur-
ing the first 100 days. Of note, the earlier reported
trend toward an improved outcome of CMV disease
after NM-HCT could not be confirmed in this study.
In addition, the study showed that the survival rate
after CMV disease was still very unfavorable, and
emphasizes the need for improved prevention and
treatment strategies for CMV. Maribavir, a novel
antiviral agent [23] and immune enhancement strate-
gies with CMV-specific T cells [24] or CMV vaccina-
tion [25] or preemptive strategies that combine
virologic and immunologic monitoring may be op-
tions in this regard.ACKNOWLEDGMENTS
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